266 related articles for article (PubMed ID: 22115852)
1. Prognostic and diagnostic significance of DNA methylation patterns in high grade serous ovarian cancer.
Montavon C; Gloss BS; Warton K; Barton CA; Statham AL; Scurry JP; Tabor B; Nguyen TV; Qu W; Samimi G; Hacker NF; Sutherland RL; Clark SJ; O'Brien PM
Gynecol Oncol; 2012 Mar; 124(3):582-8. PubMed ID: 22115852
[TBL] [Abstract][Full Text] [Related]
2. BRCA1 gene promoter methylation status in high-grade serous ovarian cancer patients--a study of the tumour Bank ovarian cancer (TOC) and ovarian cancer diagnosis consortium (OVCAD).
Ruscito I; Dimitrova D; Vasconcelos I; Gellhaus K; Schwachula T; Bellati F; Zeillinger R; Benedetti-Panici P; Vergote I; Mahner S; Cacsire-Tong D; Concin N; Darb-Esfahani S; Lambrechts S; Sehouli J; Olek S; Braicu EI
Eur J Cancer; 2014 Aug; 50(12):2090-8. PubMed ID: 24889916
[TBL] [Abstract][Full Text] [Related]
3. A cell-of-origin epigenetic tracer reveals clinically distinct subtypes of high-grade serous ovarian cancer.
Lo Riso P; Villa CE; Gasparoni G; Vingiani A; Luongo R; Manfredi A; Jungmann A; Bertolotti A; Borgo F; Garbi A; Lupia M; Laise P; Das V; Pruneri G; Viale G; Colombo N; Manzo T; Nezi L; Cavallaro U; Cacchiarelli D; Walter J; Testa G
Genome Med; 2020 Oct; 12(1):94. PubMed ID: 33121525
[TBL] [Abstract][Full Text] [Related]
4. Global methylation profiling in serous ovarian cancer is indicative for distinct aberrant DNA methylation signatures associated with tumor aggressiveness and disease progression.
Keita M; Wang ZQ; Pelletier JF; Bachvarova M; Plante M; Gregoire J; Renaud MC; Mes-Masson AM; Paquet ÉR; Bachvarov D
Gynecol Oncol; 2013 Feb; 128(2):356-63. PubMed ID: 23219462
[TBL] [Abstract][Full Text] [Related]
5. DNA methylation profiling of ovarian carcinomas and their in vitro models identifies HOXA9, HOXB5, SCGB3A1, and CRABP1 as novel targets.
Wu Q; Lothe RA; Ahlquist T; Silins I; Tropé CG; Micci F; Nesland JM; Suo Z; Lind GE
Mol Cancer; 2007 Jul; 6():45. PubMed ID: 17623056
[TBL] [Abstract][Full Text] [Related]
6. Is low-grade serous ovarian cancer part of the tumor spectrum of hereditary breast and ovarian cancer?
Vineyard MA; Daniels MS; Urbauer DL; Deavers MT; Sun CC; Boerwinkle E; Bodurka DC; Gershenson DM; Crawford J; Lu KH
Gynecol Oncol; 2011 Feb; 120(2):229-32. PubMed ID: 21126756
[TBL] [Abstract][Full Text] [Related]
7. RASSF1A promoter methylation in high-grade serous ovarian cancer: A direct comparison study in primary tumors, adjacent morphologically tumor cell-free tissues and paired circulating tumor DNA.
Giannopoulou L; Chebouti I; Pavlakis K; Kasimir-Bauer S; Lianidou ES
Oncotarget; 2017 Mar; 8(13):21429-21443. PubMed ID: 28206954
[TBL] [Abstract][Full Text] [Related]
8. A study of the methylation status of opioid binding protein/cell adhesion molecule-like gene in ovarian cancer using nested methylation-specific polymerase chain reaction detection.
Zhou F; Cao X; Liu M; Wang Y; Tao G
Clin Lab; 2011; 57(5-6):421-4. PubMed ID: 21755835
[TBL] [Abstract][Full Text] [Related]
9. Differential DNA methylation in high-grade serous ovarian cancer (HGSOC) is associated with tumor behavior.
Reyes HD; Devor EJ; Warrier A; Newtson AM; Mattson J; Wagner V; Duncan GN; Leslie KK; Gonzalez-Bosquet J
Sci Rep; 2019 Nov; 9(1):17996. PubMed ID: 31784612
[TBL] [Abstract][Full Text] [Related]
10. Interferon regulatory factor 1 is an independent predictor of platinum resistance and survival in high-grade serous ovarian carcinoma.
Cohen S; Mosig R; Moshier E; Pereira E; Rahaman J; Prasad-Hayes M; Halpert R; Billaud JN; Dottino P; Martignetti JA
Gynecol Oncol; 2014 Sep; 134(3):591-8. PubMed ID: 24995581
[TBL] [Abstract][Full Text] [Related]
11. Imprinted tumor suppressor genes ARHI and PEG3 are the most frequently down-regulated in human ovarian cancers by loss of heterozygosity and promoter methylation.
Feng W; Marquez RT; Lu Z; Liu J; Lu KH; Issa JP; Fishman DM; Yu Y; Bast RC
Cancer; 2008 Apr; 112(7):1489-502. PubMed ID: 18286529
[TBL] [Abstract][Full Text] [Related]
12. A multiplex methylation-specific PCR assay for the detection of early-stage ovarian cancer using cell-free serum DNA.
Zhang Q; Hu G; Yang Q; Dong R; Xie X; Ma D; Shen K; Kong B
Gynecol Oncol; 2013 Jul; 130(1):132-9. PubMed ID: 23623832
[TBL] [Abstract][Full Text] [Related]
13. Promoter methylation of sFRP5 in patients with ovarian clear cell adenocarcinoma.
Ho CM; Lai HC; Huang SH; Chien TY; Lin MC; Chang SF
Eur J Clin Invest; 2010 Apr; 40(4):310-8. PubMed ID: 20486992
[TBL] [Abstract][Full Text] [Related]
14. HOXA4/HOXB3 gene expression signature as a biomarker of recurrence in patients with high-grade serous ovarian cancer following primary cytoreductive surgery and first-line adjuvant chemotherapy.
Miller KR; Patel JN; Zhang Q; Norris EJ; Symanowski J; Michener C; Sehouli J; Braicu I; Destephanis DD; Sutker AP; Jones W; Livasy CA; Biscotti C; Ganapathi RN; Tait DL; Ganapathi MK
Gynecol Oncol; 2018 Apr; 149(1):155-162. PubMed ID: 29402501
[TBL] [Abstract][Full Text] [Related]
15. Integrative genome-wide expression and promoter DNA methylation profiling identifies a potential novel panel of ovarian cancer epigenetic biomarkers.
Gloss BS; Patterson KI; Barton CA; Gonzalez M; Scurry JP; Hacker NF; Sutherland RL; O'Brien PM; Clark SJ
Cancer Lett; 2012 May; 318(1):76-85. PubMed ID: 22155104
[TBL] [Abstract][Full Text] [Related]
16. Tumor specific methylome in Chinese high-grade serous ovarian cancer characterized by gene expression profile and tumor genotype.
Song F; Li L; Zhang B; Zhao Y; Zheng H; Yang M; Li X; Tian J; Huang C; Liu L; Wang Q; Zhang W; Chen K
Gynecol Oncol; 2020 Jul; 158(1):178-187. PubMed ID: 32362568
[TBL] [Abstract][Full Text] [Related]
17. Quantitative detection of RASSF1A DNA promoter methylation in tumors and serum of patients with serous epithelial ovarian cancer.
Bondurant AE; Huang Z; Whitaker RS; Simel LR; Berchuck A; Murphy SK
Gynecol Oncol; 2011 Dec; 123(3):581-7. PubMed ID: 21955482
[TBL] [Abstract][Full Text] [Related]
18. Aberrant Promoter Hypermethylation of RASSF1a and BRCA1 in Circulating Cell-Free Tumor DNA Serves as a Biomarker of Ovarian Carcinoma.
S SK; Swamy SN; Premalatha CS; Pallavi VR; Gawari R
Asian Pac J Cancer Prev; 2019 Oct; 20(10):3001-3005. PubMed ID: 31653147
[TBL] [Abstract][Full Text] [Related]
19. Methylation and expression analysis of 15 genes and three normally-methylated genes in 13 Ovarian cancer cell lines.
Imura M; Yamashita S; Cai LY; Furuta J; Wakabayashi M; Yasugi T; Ushijima T
Cancer Lett; 2006 Sep; 241(2):213-20. PubMed ID: 16303245
[TBL] [Abstract][Full Text] [Related]
20. Expression of BRCA1 protein in benign, borderline, and malignant epithelial ovarian neoplasms and its relationship to methylation and allelic loss of the BRCA1 gene.
Wang C; Horiuchi A; Imai T; Ohira S; Itoh K; Nikaido T; Katsuyama Y; Konishi I
J Pathol; 2004 Feb; 202(2):215-23. PubMed ID: 14743504
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
